PCOS symptom improvement
Multiple RCTs show myo-inositol restores ovarian function, reduces androgen levels, improves menstrual regularity, and enhances fertility in women with PCOS — effects comparable to metformin with fewer GI side effects.
BMI reduction in PCOS and metabolic conditions
A 2022 meta-analysis of 15 RCTs (891 participants) demonstrated that inositol supplementation significantly reduces BMI (WMD: -0.41 kg/m²), with the strongest effects observed in women with PCOS and overweight/obese individuals. Myo-inositol shows greater BMI-reduction effects than other forms. An RCT in obese patients with NAFLD found 4 g/day myo-inositol for 8 weeks produced a 4.72 kg average weight loss (vs. 3.27 kg in placebo) with significant reductions in waist circumference and improvements in insulin resistance, lipid profile, and liver steatosis. Mechanism: inositol restores insulin signaling via inositol phosphoglycan (IPG) second messengers, addressing the insulin resistance that underlies weight gain in PCOS and metabolic syndrome.
Insulin sensitivity
Inositol is a structural component of insulin secondary messenger molecules (IPGs). Supplementation improves insulin receptor signaling, reducing fasting glucose, insulin resistance, and metabolic syndrome markers.
Mental health support
Clinical trials show myo-inositol (12–18 g/day) reduces symptoms of OCD, panic disorder, and depression. Acts as a second messenger in serotonin and dopamine signal transduction pathways.
Egg quality and fertility
Myo-inositol improves oocyte quality, maturation rates, and embryo quality in IVF studies. Shown to reduce the dosage of FSH needed for ovarian stimulation by 25–30%.
Insulin signaling second messenger
Inositol phosphoglycans (IPGs) are intracellular mediators of insulin receptor signaling. They activate pyruvate dehydrogenase and other insulin-responsive enzymes, improving glucose utilization.
Phospholipid membrane component
Phosphatidylinositol and its phosphorylated forms (PIP, PIP2, PIP3) are essential membrane lipids serving as docking sites for signaling proteins and precursors to second messengers DAG and IP3.
Serotonin receptor coupling
IP3 (inositol trisphosphate) is a key second messenger for serotonin (5-HT2) and dopamine receptors. Inositol depletion reduces signal transduction at these receptors, providing the theoretical basis for inositol in mood disorders.
RCT comparing myo-inositol (4 g/day) vs. metformin (1,500 mg/day) in 92 women with PCOS for 12 weeks.
92 women with PCOS. 12-week intervention.
Both treatments significantly improved insulin resistance, androgen levels, and menstrual regularity. Myo-inositol showed comparable efficacy with significantly fewer GI side effects.
Double-blind crossover RCT of inositol (18 g/day) vs. fluvoxamine in 20 patients with panic disorder.
20 adults with panic disorder. 4-week crossover design.
Inositol significantly reduced frequency of panic attacks (4 per week vs. 6 with fluvoxamine). Inositol had significantly fewer side effects than fluvoxamine.